Technical Analysis for ACW - Actinogen Medical Ltd  

Grade Last Price % Change Price Change
C 0.032 3.23% 0.001
ACW closed down 3.13 percent on Monday, March 18, 2024, on 24 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Flat

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 3.23%
Narrow Range Bar Range Contraction 3.23%
Doji - Bullish? Reversal 3.23%
Wide Bands Range Expansion 3.23%
Gapped Down Weakness 3.23%
50 DMA Support Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
Doji - Bullish? Reversal 0.00%
Wide Bands Range Expansion 0.00%
Wide Bands Range Expansion 0.00%

   Recent Intraday Alerts

Alert Time
Fell Below Previous Day's Low about 5 hours ago
Down 3% about 5 hours ago
Down 2% about 5 hours ago
Down 1% about 5 hours ago
50 DMA Resistance about 6 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Actinogen Medical Ltd   Description

Actinogen Medical Limited, formerly Actinogen Limited, is a clinical-stage biotechnology company. The Company focuses on the treatment of Alzheimer's disease and age-related neurodegenerative diseases. The Company is engaged in treating cognitive impairment in chronic neurodegenerative diseases through the inhibition of cortisol production. The Company's Xanamem is a drug under development for the treatment of Alzheimer's disease, which is designed to block the production of cortisol in the brain. Xanamem's mechanism of action is to block the activity of a specific enzyme in the brain, the 11B-HSD1 enzyme. It focuses on Xanamem in the clinical areas, including Diabetes-Cognitive dysfunction, Cognitive dysfunction in Parkinson's Disease, Post Traumatic Stress Disorder (PTSD), Cognitive dysfunction in schizophrenia and depression, and Cardiovascular disease-Post myocardial infarction. It focuses on Phase II XanADu efficacy and safety study with mild Alzheimer's disease patients.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Disease Diseases Safety Diabetes Psychiatric Diagnosis Psychiatry Alzheimer's Disease Dementia Parkinson Degenerative Disease Parkinson's Disease

Is ACW a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 0.075
52 Week Low 0.015
Average Volume 3,687,363
200-Day Moving Average 0.028
50-Day Moving Average 0.032
20-Day Moving Average 0.034
10-Day Moving Average 0.032
Average True Range 0.003
RSI (14) 39.39
ADX 16.14
+DI 18.764
-DI 22.737
Chandelier Exit (Long, 3 ATRs) 0.046
Chandelier Exit (Short, 3 ATRs) 0.040
Upper Bollinger Bands 0.039
Lower Bollinger Band 0.029
Percent B (%b) 0.22
BandWidth 30.678
MACD Line -0.001
MACD Signal Line 0.000
MACD Histogram -0.0006
Fundamentals Value
Market Cap 44.97 Million
Num Shares 1.45 Billion
EPS -0.01
Price-to-Earnings (P/E) Ratio -3.44
Price-to-Sales 0.00
Price-to-Book 2.93
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.033
Resistance 3 (R3) 0.033 0.033 0.033
Resistance 2 (R2) 0.033 0.032 0.033 0.033
Resistance 1 (R1) 0.032 0.032 0.032 0.032 0.033
Pivot Point 0.031 0.031 0.031 0.031 0.031
Support 1 (S1) 0.030 0.031 0.030 0.030 0.029
Support 2 (S2) 0.030 0.030 0.030 0.029
Support 3 (S3) 0.029 0.030 0.029
Support 4 (S4) 0.029